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METHODS: We analyzed the 2004 German InEK Hospital sta-
tistics data, the 2005 French Programme de Médicalisation des
Systèmes d’Informations (PMSI) database and the 2005–06 NHS
England Hospital Episode Statistics (HES) database to estimate
the number and type of surgical procedures for POP. We included
procedures performed for uterovaginal prolapse, such as col-
porrhaphy, sacrocolpopexy and sacrospinous colpopexy. Addi-
tionally, we identiﬁed the total number of hysterectomies;
extrapolating from previous studies, we assumed 15% of these
were performed for a primary indication of POP. We multiplied
the observed number of surgical procedures by the respective
2007 Diagnosis-Related Group (DRG) reimbursement rates to
estimate the direct annual surgical cost. RESULTS: Annually,
62,581 POP repair procedures were performed in Germany,
32,392 in France and 23,583 in NHS England. In addition, we
estimate that 39,329 hysterectomies are performed for a primary
indication of POP across the three healthcare systems. The direct
surgical cost of these surgical procedures was €476M. CON-
CLUSIONS: The annual direct surgical cost of POP to the 3 big
European healthcare systems is nearly €500M, highlighting a sig-
niﬁcant burden to the European payer. This is under-estimate of
the true cost of the illness because it does not include other
medical costs, cost of conservative management and societal
costs. Extrapolating from epidemiological studies, about 30% of
POP procedures are repeat surgeries, implying the direct surgi-
cal cost of re-operations is approximately €135M. Considering
the high ﬁnancial burden of POP and its recurrence, it is imper-
ative that new standardized procedures with superior outcome
are considered, in order to effectively treat the condition, and by
doing so, reduce recurrence.
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OBJECTIVES: In 2001, excessive uterine bleeding was the cause
of 1.4 million physician visits in the US. Beyond offering con-
traceptive beneﬁts, Levonorgestrel-Releasing Intrauterine System
(LNG-IUS) is an effective alternative to traditional management
of menstrual bleeding disorders. The objective was to describe a
population on LNG-IUS and assess contraceptive and non-
contraceptive outcomes. METHODS: Women °Y´18 years of age
with LNG-IUS and °Y´1 year of continuous enrollment pre- and
post-insertion were identiﬁed via a retrospective cohort design
utilizing claims data from a Michigan vertically integrated health
care system (Jan. 2000–Dec. 2005). Patterns of LNG-IUS use,
number of obstetric- and gynecology-related visits, percent of
patients with menorrhagia, dysmenorrhea, dysfunctional uterine
bleeding, and abnormal uterine bleeding were compared pre- and
post-insertion, along with gynecology-related costs. RESULTS:
A total of 152 women (mean age 35 ± 8) met study inclusion
criteria. Two nested cohorts were distinguished further based on
follow-up length as 2-year pre/post (N = 73) and 3-year pre/post
(N = 29) groups. Over 90% had a single insertion and °Ü4% a
LNG-IUS -related complication (e.g. expulsion, perforation, or
infection). No LNG-IUS patient experienced a pregnancy with
no obstetric-related visits post-insertion for all groups. Thirteen
percent of women experienced menorrhagia in the year preced-
ing insertion, down to 12.5%, 1.2% and 0% in the 1, 2 and 3
years post-insertion. Subsequently, mean number of gynecology-
related visits decreased from 4 to 2; 7 to 4 and 9 to 4 from the
pre- to the post-insertion period for the 1, 2, and 3-year follow-
up groups, respectively. Among non-hysterectomized women,
mean gynecology-related costs decreased from $1646 per patient
in the 3 years preceding LNG-IUS to $1355 in the 3 years post-
insertion. CONCLUSION: LNG-IUS avoided pregnancy in all
patients and led to decreased bleeding-related events and gyne-
cology-related costs starting in the second year post-insertion.
Beneﬁts should become more apparent with longer follow-up.
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OBJECTIVES: Benzodiazepines are commonly prescribed for
older people. As the elderly are more susceptible to potential
adverse outcomes from benzodiazepines, it is recommended that
benzodiazepines be used for short periods with a reduced dosage.
This observational study aimed to investigate benzodiazepine
use, in terms of treatment period and mean dosage, and examine
characteristics associated with use. METHODS: This was an
observational study of randomly selected subjects enrolled in the
National Health Insurance program, aged at least 65, who
received at least one prescription for benzodiazepines in 2002.
They were grouped according to treatment period and mean
dosage. The treatment period was deﬁned as the number of days
covered by prescribed benzodiazepines. The mean dosage was
deﬁned by the average deﬁned daily dose (DDD) of each indi-
vidual. An ordered logit regression model was adopted to eval-
uate associations of characteristics with benzodiazepine usage.
RESULTS: Of the 17,024 elderly persons included, a total of
7451 had received at least one prescription for benzodiazepines.
Individuals with comorbid mental disease such as insomnia,
anxiety, and depression, and comorbid physical disease such as
cardiovascular disease, cancer, and renal disease, and previous
receipt of benzodiazepines were more likely to receive benzodi-
azepine prescriptions. Those older than 75 years, male, with
insomnia, anxiety, depression, mental disease, physical disease
such as cardiovascular disease and diabetes, previous receipt of
benzodiazepines, and higher prescription-overlap ratio were
more likely to receive longer treatment. Subjects with insomnia,
anxiety, depression, other mental disease, arthritis, previous
receipt of more benzodiazepines, and higher prescription-overlap
ratio were more likely to receive higher-dose therapy. CON-
CLUSION: According to our preliminary ﬁndings, the one-year
prevalence of benzodiazepine use among the elderly was approx-
imately 44%. Mental disorders, previous exposure to more 
benzodiazepine, and higher prescription-overlap ratio were asso-
ciated with both longer treatment and higher mean daily dose.
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OBJECTIVES: With the implementation of Medicare Part D,
managed care plans have aggressively marketed their offerings,
potentially expanding the proportion of beneﬁciaries enrolled in
Medicare managed care, known as Medicare Advantage (MA).
Growth in MA penetration has potentially important implica-
